Dr. Ernste owns stock or stock options in Amylin Pharmaceuticals.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Rheumatoid Arthritis
You have full text access to this OnlineOpen article
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases
Article first published online: 25 FEB 2011
DOI: 10.1002/art.30155
Copyright © 2011 by the American College of Rheumatology
Additional Information
How to Cite
Crowson, C. S., Matteson, E. L., Myasoedova, E., Michet, C. J., Ernste, F. C., Warrington, K. J., Davis, J. M., Hunder, G. G., Therneau, T. M. and Gabriel, S. E. (2011), The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis & Rheumatism, 63: 633–639. doi: 10.1002/art.30155
- †
Dr. Ernste owns stock or stock options in Amylin Pharmaceuticals.
Publication History
- Issue published online: 3 FEB 2011
- Article first published online: 25 FEB 2011
- Accepted manuscript online: 28 DEC 2010 04:02PM EST
- Manuscript Accepted: 9 NOV 2010
- Manuscript Received: 13 JUL 2010
Funded by
- NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Grant Number: R01-AR-46849
- Rochester Epidemiology Project from the National Institute on Aging. Grant Number: R01-AG-034676
- Abstract
- Article
- References
- Cited By
Abstract
Objective
Understanding of the personal risks for rheumatoid arthritis (RA) and other rheumatic diseases remains poor, despite advances in knowledge with regard to their pathogenesis, therapeutics, and clinical impact, in part because the personal lifetime risk of developing these diseases is unknown. This study was undertaken to estimate the lifetime risk of RA, as well as other inflammatory autoimmune rheumatic diseases, including systemic lupus erythematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjögren's syndrome, and to provide an overall estimate of the risk of developing inflammatory autoimmune rheumatic disease over a lifetime.
Methods
Using the incidence rates obtained from our population-based studies of rheumatic diseases among residents of Olmsted County, Minnesota, and mortality rates from life tables for the general population, we estimated the sex-specific lifetime risk of rheumatic disease.
Results
The lifetime risk of RA developing in US adults was 3.6% for women and 1.7% for men, and the lifetime risk of rheumatoid factor–positive RA was 2.4% for women and 1.1% for men. The second most common inflammatory autoimmune rheumatic disease was PMR, with a lifetime risk of 2.4% for women and 1.7% for men. The overall lifetime risk of inflammatory autoimmune rheumatic disease was 8.4% for women and 5.1% for men.
Conclusion
One in 12 women and 1 in 20 men will develop an inflammatory autoimmune rheumatic disease during their lifetime. These results can serve as useful guides in counseling patients regarding their lifetime risk of these conditions and have important implications regarding disease awareness campaigns.